Entera Bio Ltd. (ENTX)

Over the past six months, Entera Bio Ltd.'s stock price has decreased by 35.10%. Entera Bio congratulated the FNIH-ASBMR-SABRE team on the FDA's broad qualification of total hip BMD as a validated regulatory endpoint for novel osteoporosis drugs. The company announced new preclinical data supporting the development of a once-daily oral tablet for hypoparathyroidism. Entera Bio announced its participation in the 8th Annual Evercore ISI Healthcare Conference. The company announced its Third Quarter 2025 Financial Results and Business Updates, which included FDA agreement on BMD as a primary endpoint for the EB613 Phase 3 study and highlighted EB613 Phase 2 data. Entera Bio presented positive new clinical data from its EB613 Phase 2 trial, showing significant bone density improvements in early postmenopausal women. Entera Bio unveiled promising PK data for its first oral GLP-2 therapy. Entera Bio announced its First Quarter 2025 Financial Results and Business Updates, highlighting progress across programs and an extended cash runway into late 2026 through investments from strategic partner OPKO Health Inc. The company reported its Full Year 2024 Financial Results and provided business updates, noting a net loss of $9.5 million for the year ended December 31, 2024.

There is no indication of demand seasonality for Entera Bio Ltd.'s products and services, as demand for medical treatments is typically driven by ongoing patient needs and disease prevalence rather than seasonal fluctuations.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing orally delivered large molecule therapeutics, operating within the Healthcare sector and Biotechnology industry. The company utilizes its N-Tab platform to create oral alternatives to injectable treatments. Key product candidates include EB613 for osteoporosis, EB612 for hypoparathyroidism, oral Oxyntomodulin for obesity and metabolic disorders, and a GLP-2 peptide tablet for rare malabsorption conditions.

Entera Bio Ltd. is headquartered in Jerusalem, Israel, and is exploring opportunities to commercialize its products in global markets, particularly in regions with a high prevalence of osteoporosis and hypoparathyroidism.

Entera Bio's brand reputation has been positively influenced by key developments in its clinical programs and regulatory interactions, including positive clinical data from its Phase 2 trial for EB613 and the FDA's alignment on total hip BMD as a validated regulatory endpoint. The company has also reported promising preclinical data for its EB612 program and positive PK data for its oral GLP-2 therapy. These advancements contribute to a favorable scientific and clinical reputation.

Entera Bio Ltd. has a diverse ownership structure, with institutional shareholders holding 20.05% of the stock, Entera Bio insiders owning 16.53%, and retail investors accounting for 63.42%. Major institutional owners include Knoll Capital Management LLC, Point72 Asset Management, L.P., Marshall Wace, Llp, Schonfeld Strategic Advisors LLC, Parkman Healthcare Partners LLC, Northern Trust Corp, Bessemer Group Inc, Renaissance Technologies Llc, Susquehanna International Group, Llp, and Signature Estate & Investment Advisors Llc. In the past three months, insiders have bought more company stock than they have sold.